Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Vigeo Therapeutics New Immune Profiling and Biomarker Data Ph I/II Expansion Study in GBM Patients
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, has announced encouraging new data […]
TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma
Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer […]
Myosin Therapeutics Closes Seed Round to Continue Development of Innovative Therapies for Glioblastoma and Stimulant Use Disorder
Myosin Therapeutics, a biotechnology company leveraging its innovative platform technology to identify new molecular entities […]
Roche launches Two New Antibodies to Identify Key Clinical Mutations in Patients with Brain Cancer
Roche announced today the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more